Ann: Focussed Strategy to Maximise Growth, page-45

Yeah, interesting to see if we will get a similar valuation that Murray Meds got in that deal.

It doesnt look bad for potential buyers, I would love to have a go at running it.




Its not the best time to sell, so I bet could pick this up for bargain prices, given the current market and state of cannabis ETFs. Lets see what we get for it. $5+ mill would be a nice addition to the cash balance and would put off any need for a CR, good sale and then approval of debt facility from a bank, woud bode well for ECS.